لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Roth JD, Trevaskis JL, Wilson J, Lei C, Athanacio J, Mack C, Kesty NC, Coffey T, Weyer C, Parkes DG

المصدر: International Journal of Obesity; Aug2008, Vol. 32 Issue 8, p1201-1210, 10p

المؤلفون: Vijayakumar A; Gilead Sciences, Foster City, California, USA., Okesli-Armlovich A; Gilead Sciences, Foster City, California, USA., Wang T; Gilead Sciences, Foster City, California, USA., Olson I; Gilead Sciences, Foster City, California, USA., Seung M; Gilead Sciences, Foster City, California, USA., Kusam S; Gilead Sciences, Foster City, California, USA., Hollenback D; Gilead Sciences, Foster City, California, USA., Mahadevan S; Gilead Sciences, Foster City, California, USA., Marchand B; Gilead Sciences, Foster City, California, USA., Toteva M; Gilead Sciences, Foster City, California, USA., Breckenridge DG; Gilead Sciences, Foster City, California, USA., Trevaskis JL; Gilead Sciences, Foster City, California, USA., Bates J; Gilead Sciences, Foster City, California, USA.

المصدر: Hepatology communications [Hepatol Commun] 2022 Sep; Vol. 6 (9), pp. 2298-2309. Date of Electronic Publication: 2022 Jun 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101695860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2471-254X (Electronic) Linking ISSN: 2471254X NLM ISO Abbreviation: Hepatol Commun Subsets: MEDLINE

مواضيع طبية MeSH: Fenofibrate*/pharmacology , Hypertriglyceridemia* , Non-alcoholic Fatty Liver Disease*/drug therapy, Acetates ; Acetyl-CoA Carboxylase ; Animals ; Humans ; Liver Cirrhosis/chemically induced ; PPAR alpha/therapeutic use ; Rats ; Triglycerides/therapeutic use

المؤلفون: Hyrina A; Gilead Sciences, Inc., Foster City, California, United States of America., Burdette D; Gilead Sciences, Inc., Foster City, California, United States of America., Song Z; Gilead Sciences, Inc., Foster City, California, United States of America., Ramirez R; Gilead Sciences, Inc., Foster City, California, United States of America., Okesli-Armlovich A; Gilead Sciences, Inc., Foster City, California, United States of America., Vijayakumar A; Gilead Sciences, Inc., Foster City, California, United States of America., Bates J; Gilead Sciences, Inc., Foster City, California, United States of America., Trevaskis JL; Gilead Sciences, Inc., Foster City, California, United States of America., Fletcher SP; Gilead Sciences, Inc., Foster City, California, United States of America., Lee WA; Gilead Sciences, Inc., Foster City, California, United States of America., Holdorf MM; Gilead Sciences, Inc., Foster City, California, United States of America.

المصدر: PloS one [PLoS One] 2022 Aug 04; Vol. 17 (8), pp. e0270273. Date of Electronic Publication: 2022 Aug 04 (Print Publication: 2022).

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Hepatitis B* , Hepatitis B, Chronic*/drug therapy, Animals ; Antiviral Agents/metabolism ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; DNA, Viral/metabolism ; Hepatitis B Surface Antigens/metabolism ; Hepatitis B virus/genetics ; Lipids/therapeutic use ; Mice ; Mice, SCID

المؤلفون: Boland BB; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Gubra ApS, Horsholm, Denmark; PRECISIONscientia, Yardley, PA, USA., Laker RC; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., O'Brien S; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sitaula S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Sermadiras I; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Nielsen JC; Gubra ApS, Horsholm, Denmark., Barkholt P; Gubra ApS, Horsholm, Denmark., Roostalu U; Gubra ApS, Horsholm, Denmark., Hecksher-Sørensen J; Gubra ApS, Horsholm, Denmark., Sejthen SR; Gubra ApS, Horsholm, Denmark., Thorbek DD; Gubra ApS, Horsholm, Denmark., Suckow A; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; DTX Pharma, San Diego, CA, USA., Burmeister N; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Roche, Penzberg, Germany., Oldham S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Will S; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Howard VG; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Gill BM; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Newton P; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Antibody and Protein Engineering, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Naylor J; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Hornigold DC; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Austin J; University of Chicago Advanced Electron Microscopy Core Facility, Chicago, IL, USA., Lantier L; Vanderbilt University Mouse Metabolic Phenotyping Center, Nashville, TN, USA., McGuinness OP; Vanderbilt University Mouse Metabolic Phenotyping Center, Nashville, TN, USA., Trevaskis JL; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK; Gilead Sciences, Foster City, CA, USA., Grimsby JS; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Rhodes CJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address: christopher.rhodes@astrazeneca.com.

المصدر: Molecular metabolism [Mol Metab] 2022 Jan; Vol. 55, pp. 101392. Date of Electronic Publication: 2021 Nov 12.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Elsevier GmbH Country of Publication: Germany NLM ID: 101605730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-8778 (Electronic) Linking ISSN: 22128778 NLM ISO Abbreviation: Mol Metab Subsets: MEDLINE

مواضيع طبية MeSH: Glucagon-Like Peptide 1/*metabolism , Obesity/*metabolism , Peptide YY/*metabolism, Animals ; Blood Glucose/metabolism ; Body Weight/drug effects ; Diabetes Mellitus, Experimental/metabolism ; Diabetes Mellitus, Type 2/metabolism ; Diet ; Eating/drug effects ; Energy Intake/drug effects ; Energy Metabolism/drug effects ; Gastric Bypass ; Glucagon-Like Peptide-1 Receptor/metabolism ; Hypothalamus ; Insulin Resistance/physiology ; Insulin-Secreting Cells/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Mice, Obese ; Obesity/physiopathology ; Peptide YY/physiology ; Weight Loss

المؤلفون: Roth E; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Benoit S; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Quentin B; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Lam B; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Will S; Cardiovascular, Renal, and Metabolic Diseases, MedImmune LLC, Gaithersburg, MD 20878, USA., Ma M; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Heeley N; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Darwish T; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Shrestha Y; Early Oncology, Translational Medicine, MedImmune LLC, Gaithersburg, MD 20878, USA., Gribble F; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Reimann F; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Pshenichnaya I; Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, UK., Yeo G; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK., Baker DJ; Cardiovascular, Renal and Metabolic Diseases, MedImmune Ltd., Cambridge, UK., Trevaskis JL; Cardiovascular, Renal and Metabolic Diseases, MedImmune Ltd., Cambridge, UK., Blouet C; MRC Metabolic Diseases Unit, University of Cambridge Metabolic Research Laboratories, WT-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 OQQ, UK. Electronic address: csb69@medschl.cam.ac.uk.

المصدر: Molecular metabolism [Mol Metab] 2021 Jan; Vol. 43, pp. 101118. Date of Electronic Publication: 2020 Nov 19.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier GmbH Country of Publication: Germany NLM ID: 101605730 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2212-8778 (Electronic) Linking ISSN: 22128778 NLM ISO Abbreviation: Mol Metab Subsets: MEDLINE

مواضيع طبية MeSH: Glucagon-Like Peptide-1 Receptor/*metabolism , Obesity/*drug therapy , Receptors, Cholecystokinin/*metabolism, Animals ; Anti-Obesity Agents/pharmacology ; Appetite Regulation ; Brain/metabolism ; Diet, High-Fat ; Eating/drug effects ; Feeding Behavior/drug effects ; Glucagon-Like Peptide 1/pharmacology ; Glucagon-Like Peptide-1 Receptor/drug effects ; Male ; Mice ; Mice, Inbred C57BL ; Neurons/metabolism ; Obesity/metabolism ; Solitary Nucleus/metabolism ; Weight Loss/drug effects

المؤلفون: Hansen HH; Gubra, DK-2970, Hørsholm, Denmark. hbh@gubra.dk., Ægidius HM; Gubra, DK-2970, Hørsholm, Denmark., Oró D; Gubra, DK-2970, Hørsholm, Denmark., Evers SS; Gubra, DK-2970, Hørsholm, Denmark., Heebøll S; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Eriksen PL; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Thomsen KL; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Bengtsson A; Gubra, DK-2970, Hørsholm, Denmark., Veidal SS; Gubra, DK-2970, Hørsholm, Denmark., Feigh M; Gubra, DK-2970, Hørsholm, Denmark., Suppli MP; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark., Knop FK; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Grønbæk H; Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark., Miranda D; Gilead Sciences, Foster City, CA, USA., Trevaskis JL; Gilead Sciences, Foster City, CA, USA., Vrang N; Gubra, DK-2970, Hørsholm, Denmark., Jelsing J; Gubra, DK-2970, Hørsholm, Denmark., Rigbolt KTG; Gubra, DK-2970, Hørsholm, Denmark.

المصدر: BMC gastroenterology [BMC Gastroenterol] 2020 Jul 06; Vol. 20 (1), pp. 210. Date of Electronic Publication: 2020 Jul 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100968547 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-230X (Electronic) Linking ISSN: 1471230X NLM ISO Abbreviation: BMC Gastroenterol Subsets: MEDLINE

مواضيع طبية MeSH: Non-alcoholic Fatty Liver Disease*, Animals ; Diet, High-Fat/adverse effects ; Disease Models, Animal ; Humans ; Liver ; Mice ; Mice, Inbred C57BL ; Mice, Obese ; Obesity/complications

المؤلفون: Boland ML; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Laker RC; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Mather K; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Nawrocki A; Department of Biochemistry and Molecular Biology, PR group, University of Southern Denmark, Odense, Denmark., Oldham S; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Boland BB; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Lewis H; Research and Early Development, Oncology, AstraZeneca, Cambridge, UK., Conway J; Translational Sciences, AstraZeneca, Gaithersburg, MD, USA., Naylor J; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Guionaud S; Global Pathology, AstraZeneca, Cambridge, UK., Feigh M; Gubra, Hørsholm, Denmark., Veidal SS; Gubra, Hørsholm, Denmark., Lantier L; Vanderbilt University Mouse Metabolic Phenotyping Center, Nashville, TN, USA., McGuinness OP; Vanderbilt University Mouse Metabolic Phenotyping Center, Nashville, TN, USA., Grimsby J; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Rondinone CM; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Jermutus L; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Larsen MR; Department of Biochemistry and Molecular Biology, PR group, University of Southern Denmark, Odense, Denmark., Trevaskis JL; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.; Gilead Sciences, Foster City, CA, USA., Rhodes CJ; Research and Early Development, Cardiovascular, Renal and Metabolic Diseases, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. Christopher.Rhodes@astrazeneca.com.

المصدر: Nature metabolism [Nat Metab] 2020 May; Vol. 2 (5), pp. 413-431. Date of Electronic Publication: 2020 May 21.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Springer Nature Country of Publication: Germany NLM ID: 101736592 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2522-5812 (Electronic) Linking ISSN: 25225812 NLM ISO Abbreviation: Nat Metab

مواضيع طبية MeSH: Glucagon-Like Peptide-1 Receptor/*agonists , Lipogenesis/*drug effects , Liver Cirrhosis/*drug therapy , Mitochondria/*drug effects , Non-alcoholic Fatty Liver Disease/*drug therapy , Peptides/*therapeutic use, Animals ; Blood Glucose/metabolism ; Body Weight ; Diabetes Mellitus, Type 2/complications ; Glucagon-Like Peptide-1 Receptor/genetics ; Glycogen/metabolism ; Liver/drug effects ; Liver/enzymology ; Liver/metabolism ; Liver Cirrhosis/metabolism ; Male ; Mice ; Mice, Knockout ; Mitochondria/metabolism ; Non-alcoholic Fatty Liver Disease/metabolism ; Proteomics

المؤلفون: McMahon C; Gilead Sciences Inc., Foster City, CA, United States of America., Trevaskis JL; Gilead Sciences Inc., Foster City, CA, United States of America., Carter C; Gilead Sciences Inc., Foster City, CA, United States of America., Holsapple K; Gilead Sciences Inc., Foster City, CA, United States of America., White K; Gilead Sciences Inc., Foster City, CA, United States of America., Das M; Gilead Sciences Inc., Foster City, CA, United States of America., Collins S; Gilead Sciences Inc., Foster City, CA, United States of America., Martin H; Gilead Sciences Inc., Foster City, CA, United States of America., Burns-Naas LA; Gilead Sciences Inc., Foster City, CA, United States of America.

المصدر: PloS one [PLoS One] 2020 Feb 28; Vol. 15 (2), pp. e0229617. Date of Electronic Publication: 2020 Feb 28 (Print Publication: 2020).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: HIV Integrase Inhibitors/*adverse effects , Receptor, Melanocortin, Type 4/*drug effects , Weight Gain/*drug effects, Body Weight ; HIV Infections/drug therapy ; HIV Integrase Inhibitors/pharmacology ; HIV Integrase Inhibitors/therapeutic use ; Humans ; Receptor, Melanocortin, Type 4/agonists ; Receptor, Melanocortin, Type 4/antagonists & inhibitors